These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DELAWARE
|
|
95-4405754
|
|
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
Large accelerated filer
x
|
|
Accelerated filer
o
|
|
|
Non-accelerated filer
o
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
o
|
|
|
ACACIA RESEARCH CORPORATION
|
|||
|
Table Of Contents
|
|||
|
|
|
|
|
|
Part I.
|
Financial Information
|
|
|
|
|
|
|
|
|
|
Item 1.
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 2.
|
||
|
|
|
|
|
|
|
Item 3.
|
||
|
|
|
|
|
|
|
Item 4.
|
||
|
|
|
|
|
|
|
|
|
|
|
Part II.
|
Other Information
|
||
|
|
|
|
|
|
|
Item 6.
|
||
|
|
|
|
|
|
|
|
|
|
|
Signatures
|
|
||
|
|
|
|
|
|
Exhibit Index
|
|
||
|
|
March 31,
2012 |
|
December 31,
2011 |
||||
|
ASSETS
|
|
|
|
||||
|
Current assets:
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
315,498
|
|
|
$
|
314,733
|
|
|
Short-term investments
|
134,185
|
|
|
6,597
|
|
||
|
Accounts receivable
|
1,280
|
|
|
2,915
|
|
||
|
Prepaid expenses and other current assets
|
2,431
|
|
|
803
|
|
||
|
Total current assets
|
453,394
|
|
|
325,048
|
|
||
|
|
|
|
|
|
|
||
|
Property and equipment, net of accumulated depreciation
|
212
|
|
|
220
|
|
||
|
Patents, net of accumulated amortization
|
171,262
|
|
|
25,188
|
|
||
|
Goodwill
|
36,202
|
|
|
—
|
|
||
|
Investments - noncurrent
|
1,956
|
|
|
1,956
|
|
||
|
Other assets
|
465
|
|
|
465
|
|
||
|
|
$
|
663,491
|
|
|
$
|
352,877
|
|
|
|
|
|
|
|
|
||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
||
|
Current liabilities:
|
|
|
|
|
|
||
|
Accounts payable and accrued expenses
|
$
|
8,407
|
|
|
$
|
6,625
|
|
|
Royalties and contingent legal fees payable
|
14,095
|
|
|
23,508
|
|
||
|
Total current liabilities
|
22,502
|
|
|
30,133
|
|
||
|
|
|
|
|
||||
|
Deferred income taxes
|
32,363
|
|
|
—
|
|
||
|
Other liabilities
|
642
|
|
|
632
|
|
||
|
Total liabilities
|
55,507
|
|
|
30,765
|
|
||
|
Commitments and contingencies (Note 5)
|
|
|
|
|
|
||
|
Stockholders' equity:
|
|
|
|
|
|
||
|
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued or outstanding
|
—
|
|
|
—
|
|
||
|
Common stock, par value $0.001 per share; 100,000,000 shares authorized; 49,700,283 and 42,928,001 shares issued and outstanding as of March 31, 2012 and December 31, 2011, respectively
|
50
|
|
|
43
|
|
||
|
Additional paid-in capital
|
618,683
|
|
|
386,821
|
|
||
|
Accumulated comprehensive income (loss)
|
600
|
|
|
(1,830
|
)
|
||
|
Accumulated deficit
|
(15,157
|
)
|
|
(65,085
|
)
|
||
|
Total Acacia Research Corporation stockholders' equity
|
604,176
|
|
|
319,949
|
|
||
|
Noncontrolling interests in operating subsidiaries
|
3,808
|
|
|
2,163
|
|
||
|
Total stockholders' equity
|
607,984
|
|
|
322,112
|
|
||
|
|
$
|
663,491
|
|
|
$
|
352,877
|
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2012
|
|
2011
|
||||
|
|
|
|
|
||||
|
Revenues
|
$
|
99,040
|
|
|
$
|
61,130
|
|
|
Operating costs and expenses:
|
|
|
|
|
|
||
|
Cost of revenues:
|
|
|
|
|
|
||
|
Inventor royalties
|
7,594
|
|
|
13,089
|
|
||
|
Contingent legal fees
|
3,748
|
|
|
9,367
|
|
||
|
Litigation and licensing expenses - patents
|
3,381
|
|
|
3,534
|
|
||
|
Amortization of patents
|
5,126
|
|
|
3,772
|
|
||
|
Marketing, general and administrative expenses (including non-cash stock compensation expense of $5,090 for the three months ended March 31, 2012, and $2,901 for the three months ended March 31, 2011)
|
13,731
|
|
|
9,985
|
|
||
|
Research, consulting and other expenses - business development
|
1,116
|
|
|
708
|
|
||
|
Total operating costs and expenses
|
34,696
|
|
|
40,455
|
|
||
|
Operating income
|
64,344
|
|
|
20,675
|
|
||
|
|
|
|
|
|
|
||
|
Interest and investment income
|
56
|
|
|
29
|
|
||
|
Income from operations before provision for income taxes
|
64,400
|
|
|
20,704
|
|
||
|
Provision for income taxes
|
(14,747
|
)
|
|
(7,148
|
)
|
||
|
Net income including noncontrolling interests in operating subsidiaries
|
49,653
|
|
|
13,556
|
|
||
|
Net (income) loss attributable to noncontrolling interests in operating subsidiaries
|
275
|
|
|
(1,203
|
)
|
||
|
Net income attributable to Acacia Research Corporation
|
$
|
49,928
|
|
|
$
|
12,353
|
|
|
|
|
|
|
|
|
||
|
Net income per common share attributable to Acacia Research Corporation:
|
|
|
|
|
|
||
|
Basic earnings per share
|
$
|
1.13
|
|
|
$
|
0.35
|
|
|
Diluted earnings per share
|
$
|
1.09
|
|
|
$
|
0.34
|
|
|
Weighted average number of shares outstanding, basic
|
44,367,499
|
|
|
35,182,811
|
|
||
|
Weighted average number of shares outstanding, diluted
|
45,771,228
|
|
|
36,448,005
|
|
||
|
|
Three Months Ended March 31,
|
||||||
|
|
2012
|
|
2011
|
||||
|
|
|
|
|
||||
|
Net income attributable to Acacia Research Corporation
|
$
|
49,928
|
|
|
$
|
12,353
|
|
|
Other comprehensive income:
|
|
|
|
|
|
||
|
Unrealized gain on short-term investments, net of income tax of $396 for the three months ended March 31, 2012, and $0 for the three months ended March 31, 2011
|
2,430
|
|
|
—
|
|
||
|
Comprehensive income
|
$
|
52,358
|
|
|
$
|
12,353
|
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2012
|
|
2011
|
||||
|
Cash flows from operating activities:
|
|
|
|
||||
|
Net income including noncontrolling interests in operating subsidiaries
|
$
|
49,653
|
|
|
$
|
13,556
|
|
|
Adjustments to reconcile net income including noncontrolling interests in operating subsidiaries to net cash provided by operating activities:
|
|
|
|
|
|
||
|
Depreciation and amortization
|
5,158
|
|
|
3,794
|
|
||
|
Non-cash stock compensation
|
5,090
|
|
|
2,901
|
|
||
|
Change in valuation allowance
|
(10,237
|
)
|
|
—
|
|
||
|
Other
|
—
|
|
|
(9
|
)
|
||
|
Changes in assets and liabilities:
|
|
|
|
|
|||
|
Accounts receivable
|
1,635
|
|
|
6,789
|
|
||
|
Prepaid expenses and other assets
|
(919
|
)
|
|
(337
|
)
|
||
|
Accounts payable and accrued expenses
|
2,692
|
|
|
782
|
|
||
|
Royalties and contingent legal fees payable
|
(9,413
|
)
|
|
8,976
|
|
||
|
Deferred income tax
|
5,293
|
|
|
—
|
|
||
|
|
|
|
|
||||
|
Net cash provided by operating activities
|
48,952
|
|
|
36,452
|
|
||
|
|
|
|
|
|
|
||
|
Cash flows from investing activities:
|
|
|
|
|
|
||
|
Purchases of property and equipment
|
(24
|
)
|
|
(59
|
)
|
||
|
Purchase of available-for-sale investments
|
(144,762
|
)
|
|
—
|
|
||
|
Maturities and sale of available-for-sale investments
|
20,000
|
|
|
35
|
|
||
|
Purchase of ADAPTIX, Inc., net of cash acquired
|
(150,000
|
)
|
|
—
|
|
||
|
Patent acquisition costs
|
(2,100
|
)
|
|
(680
|
)
|
||
|
|
|
|
|
||||
|
Net cash used in investing activities
|
(276,886
|
)
|
|
(704
|
)
|
||
|
|
|
|
|
|
|
||
|
Cash flows from financing activities:
|
|
|
|
|
|
||
|
Proceeds from sale of common stock, net of issuance costs
|
219,084
|
|
|
175,284
|
|
||
|
Distributions to noncontrolling interests in operating subsidiary
|
—
|
|
|
(880
|
)
|
||
|
Contributions from noncontrolling interests in operating subsidiary
|
1,920
|
|
|
877
|
|
||
|
Excess tax benefits from stock-based compensation
|
7,611
|
|
|
23
|
|
||
|
Proceeds from exercises of stock options
|
84
|
|
|
44
|
|
||
|
|
|
|
|
||||
|
Net cash provided by financing activities
|
228,699
|
|
|
175,348
|
|
||
|
|
|
|
|
|
|
||
|
Increase in cash and cash equivalents
|
765
|
|
|
211,096
|
|
||
|
|
|
|
|
|
|
||
|
Cash and cash equivalents, beginning
|
314,733
|
|
|
102,515
|
|
||
|
|
|
|
|
|
|
||
|
Cash and cash equivalents, ending
|
$
|
315,498
|
|
|
$
|
313,611
|
|
|
|
●
|
Level 1 - Observable Inputs: Quoted prices in active markets for identical investments;
|
|
|
●
|
Level 2 - Pricing Models with Significant Observable Inputs: Other significant observable inputs, including quoted prices for similar investments, interest rates, credit risk, etc.; and
|
|
|
●
|
Level 3 - Unobservable Inputs: Significant unobservable inputs, including the entity’s own assumptions in determining the fair value of investments.
|
|
|
Three Months Ended March 31,
|
||||
|
|
2012
|
|
2011
|
||
|
|
|
|
|
||
|
Weighted-average common shares outstanding - basic
|
44,367,499
|
|
|
35,182,811
|
|
|
Dilutive effect of Equity-based Incentive Awards
|
1,403,729
|
|
|
1,265,194
|
|
|
Weighted-average common shares outstanding - diluted
|
45,771,228
|
|
|
36,448,005
|
|
|
|
|
|
|
|
|
|
Anti-dilutive Equity-based Incentive Awards excluded from the computation of diluted income per share
|
7,000
|
|
|
7,760
|
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2012
|
|
2011
|
||||
|
|
|
|
|
||||
|
Balance as of January 1
|
$
|
1,956
|
|
|
$
|
2,001
|
|
|
Total gains (realized or unrealized):
|
|
|
|
|
|
||
|
Recognized gains included in earnings
(1)
|
—
|
|
|
9
|
|
||
|
Settlements
|
—
|
|
|
(35
|
)
|
||
|
Balance as of March 31
|
$
|
1,956
|
|
|
$
|
1,975
|
|
|
|
|
|
|
Amortization Period
|
|
Annual Amortization
|
|||
|
Assets Acquired and Liabilities Assumed:
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|||
|
Fair value of net tangible assets acquired
|
|
$
|
10,000
|
|
|
|
|
|
|
|
Intangible assets acquired - patents
|
|
150,000
|
|
|
10 years
|
|
15,000
|
|
|
|
Goodwill
|
|
36,202
|
|
|
|
|
|
||
|
Net deferred income tax liability
|
|
(36,202
|
)
|
|
|
|
|
||
|
Total
|
|
$
|
160,000
|
|
|
|
|
|
|
|
|
|
Book Basis
|
|
Tax Basis
|
|
Difference
|
||||||
|
|
|
|
|
|
|
|
||||||
|
Intangible assets acquired - patents
|
|
$
|
150,000
|
|
|
$
|
—
|
|
|
$
|
(150,000
|
)
|
|
Estimated net operating loss carryforwards - ADAPTIX
|
|
—
|
|
|
46,565
|
|
|
46,565
|
|
|||
|
Net deferred tax liability - pretax
|
|
|
|
|
|
(103,435
|
)
|
|||||
|
Estimated tax rate
|
|
|
|
|
|
35
|
%
|
|||||
|
Estimated net deferred tax liability
|
|
|
|
|
|
$
|
(36,202
|
)
|
||||
|
|
Three Months Ended March 31,
|
||||||
|
|
2012
|
|
2011
|
||||
|
|
|
|
|
||||
|
Revenues
|
$
|
99,040
|
|
|
$
|
61,130
|
|
|
Total operating costs and expenses
|
35,334
|
|
|
44,485
|
|
||
|
Operating income
|
63,706
|
|
|
16,645
|
|
||
|
Total other income
|
56
|
|
|
29
|
|
||
|
Income from operations before provision for income taxes
|
63,762
|
|
|
16,674
|
|
||
|
Provision for income taxes
|
(14,747
|
)
|
|
(7,148
|
)
|
||
|
Net income including noncontrolling interests in operating subsidiaries
|
49,015
|
|
|
9,526
|
|
||
|
Net (income) loss attributable to noncontrolling interests in operating subsidiaries
|
275
|
|
|
(1,203
|
)
|
||
|
Net income attributable to Acacia Research Corporation
|
$
|
49,290
|
|
|
$
|
8,323
|
|
|
|
|
|
|
|
|
||
|
|
Three Months Ended March 31,
|
||||||
|
|
2012
|
|
2011
|
||||
|
|
|
|
|
||||
|
|
|
|
|
|
|
||
|
Pro forma income per common share attributable to Acacia Research Corporation:
|
|
|
|
|
|
||
|
Basic earnings per share
|
$
|
1.11
|
|
|
$
|
0.24
|
|
|
Diluted earnings per share
|
$
|
1.08
|
|
|
$
|
0.23
|
|
|
Weighted average number of shares outstanding, basic
|
44,367,499
|
|
|
35,182,811
|
|
||
|
Weighted average number of shares outstanding, diluted
|
45,771,228
|
|
|
36,448,005
|
|
||
|
|
Three Months Ended March 31,
|
||||||
|
|
2012
|
|
2011
|
||||
|
|
|
|
|
||||
|
Revenues (in thousands)
|
$
|
99,040
|
|
|
$
|
61,130
|
|
|
New agreements executed
|
40
|
|
|
35
|
|
||
|
Licensing and enforcement programs generating revenues
|
32
|
|
|
32
|
|
||
|
Licensing and enforcement programs with initial revenues
|
6
|
|
|
8
|
|
||
|
New patent portfolios
|
5
|
|
|
8
|
|
||
|
Cumulative number of licensing and enforcement programs generating revenues - inception to date
|
118
|
|
|
99
|
|
||
|
As of Date:
|
|
Trailing Twelve -Month Revenues
|
|
% Change
|
|||
|
|
|
|
|
|
|||
|
March 31, 2012
|
|
$
|
222,617
|
|
|
21
|
%
|
|
December 31, 2011
|
|
184,707
|
|
|
4
|
%
|
|
|
September 30, 2011
|
|
177,014
|
|
|
(1
|
)%
|
|
|
June 30, 2011
|
|
177,927
|
|
|
16
|
%
|
|
|
March 31, 2011
|
|
153,187
|
|
|
—
|
%
|
|
|
•
|
4G Wireless technology
(1)
|
|
•
|
Medical Monitoring technology
|
|
•
|
Audio Communications Fraud Detection technology
|
|
•
|
Messaging technology
|
|
•
|
Camera Support technology
|
|
•
|
Network Monitoring technology
|
|
•
|
Consumer Rewards technology
(1)
|
|
•
|
NOR Flash technology
|
|
•
|
Data Compression technology
|
|
•
|
Online Auction Guarantee technology
|
|
•
|
DDR SDRAM technology
|
|
•
|
Optical Recording technology
|
|
•
|
Digital Signal Processing Architecture technology
|
|
•
|
Pop-up Internet Advertising technology
|
|
•
|
Disk Array Systems & Storage Area Network technology
|
|
•
|
Power-over-Ethernet technology
|
|
•
|
DMT® technology
|
|
•
|
Rule Based Monitoring technology
|
|
•
|
Document Generation technology
|
|
•
|
Semiconductor Memory and Process Patents technology
(1)
|
|
•
|
Impact Instrument technology
|
|
•
|
Shape Memory Alloys technology
|
|
•
|
Improved Anti-Trap Safety Technology for Vehicles technology
(1)
|
|
•
|
Telematics technology
|
|
•
|
Improved Lighting technology
|
|
•
|
User Programmable Engine Control technology
|
|
•
|
Improved Memory Manufacturing technology
(1)
|
|
•
|
Video Encoding technology
|
|
•
|
Lighting Ballast technology
|
|
•
|
Visual Data Evaluation technology
|
|
•
|
Location Based Services technology
|
|
•
|
Voice-Over-IP technology
(1)
|
|
(1)
|
Initial revenues recognized during the three months ended March 31, 2012.
|
|
•
|
Audio Communications Fraud Detection technology
|
|
•
|
Messaging technology
(1)
|
|
•
|
Camera Support technology
|
|
•
|
Microprocessor Enhancement technology
|
|
•
|
Catheter Insertion technology
(1)
|
|
•
|
Mobile Computer Synchronization technology
|
|
•
|
Computer Architecture and Power Management technology
(1)
|
|
•
|
Network Remote Access technology
|
|
•
|
Computer Graphics technology
|
|
•
|
NOR Flash technology
(1)
|
|
•
|
Digital Video Enhancement technology
|
|
•
|
Online Auction Guarantee technology
|
|
•
|
DMT® technology
|
|
•
|
Optical Switching technology
|
|
•
|
Document Generation technology
|
|
•
|
Pop-up Internet Advertising technology
|
|
•
|
Facilities Operation Management System technology
|
|
•
|
Power Management Within Integrated Circuits technology
(1)
|
|
•
|
Image Resolution Enhancement technology
|
|
•
|
Rule Based Monitoring technology
|
|
•
|
Improved Commercial Print technology
|
|
•
|
Storage technology
|
|
•
|
Interactive Mapping technology
|
|
•
|
Telematics technology
|
|
•
|
Lighting Control technology
(1)
|
|
•
|
User Programmable Engine Control technology
(1)
|
|
•
|
Location Based Services technology
|
|
•
|
Virtual Server technology
|
|
•
|
Magnetic Storage technology
(1)
|
|
•
|
Visual Data Evaluation technology
|
|
•
|
Manufacturing Data Transfer technology
|
|
•
|
Website Crawling technology
|
|
(1)
|
Initial revenues recognized during the three months ended March 31, 2011.
|
|
|
Three Months Ended March 31,
|
|
%
|
|||||||
|
|
2012
|
|
2011
|
|
Change
|
|||||
|
|
|
|
|
|
|
|||||
|
Revenues
|
$
|
99,040
|
|
|
$
|
61,130
|
|
|
62
|
%
|
|
|
|
|
|
|
|
|||||
|
Operating costs and expenses
|
34,696
|
|
|
40,455
|
|
|
(14
|
)%
|
||
|
Operating income
|
64,344
|
|
|
20,675
|
|
|
211
|
%
|
||
|
Provision for income taxes
|
(14,747
|
)
|
|
(7,148
|
)
|
|
106
|
%
|
||
|
Net income attributable to Acacia Research Corporation
|
49,928
|
|
|
12,353
|
|
|
*
|
|||
|
•
|
Revenues increased
$37.9 million
, or
62%
, to
$99.0 million
, as compared to
$61.1 million
in the prior year period.
|
|
•
|
Cost of Revenues and Other Operating Expenses:
|
|
◦
|
Inventor royalties and contingent legal fees, on a combined basis, decreased
$11.1 million
, or
49%
, as compared to the
62%
increase in related revenues due primarily to a greater percentage of revenues generated during the three months ended
March 31, 2012
having no inventor royalty or contingent legal fee arrangement obligations, as compared to the revenues generated during the three months ended
March 31, 2011
.
|
|
◦
|
Litigation and licensing expenses-patents decreased
$153,000
, or
4%
, to
$3.4 million
,
due primarily to lower net levels of litigation support, third-party technical consulting and professional expert expenses associated with our continued investment in ongoing licensing and enforcement programs. The decrease was partially offset by an increase in litigation and licensing expenses incurred in connection with our continued investment in new licensing and enforcement programs commenced since the end of the prior year period.
|
|
◦
|
Marketing, general and administrative expenses increased
$3.7 million
, or
38%
, to
$13.7 million
,
due primarily to an increase in non-cash stock compensation charges resulting from an increase in the average grant date fair value of restricted shares expensed during the three months ended
March 31, 2012
.
|
|
◦
|
Research, consulting and other expenses-business development increased
$408,000
, or
58%
, to
$1.1 million
, due primarily to a net increase in third-party research, consulting and other due diligence related costs incurred in connection with the identification, review, and assessment of patent portfolio acquisition opportunities during the three months ended
March 31, 2012
.
|
|
◦
|
Provision for income taxes increased
$7.6 million
, or
106%
, to
$14.7 million
. Tax expense for financial reporting purposes for the periods presented was calculated without the excess tax benefits related to the exercise and vesting of equity-based incentive awards. Acacia's effective tax rate for the
three months
ended
March 31, 2012
was
23%
, reflecting the impact of the income tax benefit associated with the release of valuation allowance primarily resulting from the ADAPTIX acquisition, as described at Note 2 to the consolidated financial statements herein. As of March 31, 2012, taxes paid or payable totaled approximately $12.1 million, primarily comprised of foreign withholding taxes paid of $11.9 million, and other state related taxes payable. The first quarter 2012 tax provision provides for the utilization of the $11.9 million in foreign taxes withheld in the first quarter of 2012 as a credit against income tax expense calculated for financial statement purposes. Refer to "Comparison of Results of Operations" below for additional information.
|
|
•
|
In January 2012, we acquired patents relating to
catheter ablation technology.
|
|
•
|
In January 2012, we acquired patents relating to online user registration technology.
|
|
•
|
In January 2012, we acquired rights to patents relating to optical networking technology.
|
|
•
|
In February 2012, we acquired over 300 patents from Automotive Technologies International relating to numerous automotive safety, navigation and diagnostics technologies.
|
|
•
|
Increases in patent-related legal expenses, including, but not limited to, increases in costs billed by outside legal counsel for discovery, depositions, economic analyses, damages assessments, expert witnesses and other consultants, case-related audio/video presentations and other litigation support and administrative costs, could increase our operating costs and decrease our revenue generating opportunities;
|
|
•
|
Our patented technologies and enforcement actions are complex, and, as a result, we may be required to appeal adverse decisions by trial courts in order to successfully enforce our patents;
|
|
•
|
New legislation, regulations or rules related to enforcement actions could significantly increase our operating costs and decrease our revenue generating opportunities; and
|
|
•
|
Courts may rule that our subsidiaries have violated certain statutory, regulatory, federal, local or governing rules or standards by pursuing such enforcement actions, which may expose us and our operating subsidiaries to material liabilities, which could harm our operating results and our financial position.
|
|
|
|
Three Months Ended March 31,
|
||||||
|
|
|
2012
|
|
2011
|
||||
|
|
|
|
|
|
||||
|
Revenues
|
|
$
|
99,040
|
|
|
$
|
61,130
|
|
|
|
|
Three Months Ended March 31,
|
||||
|
|
|
2012
|
|
2011
|
||
|
|
|
|
|
|
||
|
New agreements executed
|
|
40
|
|
|
35
|
|
|
Licensing and enforcement programs with initial revenues
|
|
6
|
|
|
8
|
|
|
•
|
the dollar amount of agreements executed each period, which can be driven by the nature and characteristics of the technology or technologies being licensed and the magnitude of infringement associated with a specific licensee;
|
|
•
|
the specific terms and conditions of agreements executed each period, including the nature and characteristics of rights granted, and the periods of infringement or term of use contemplated by the respective payments;
|
|
•
|
fluctuations in the total number of agreements executed;
|
|
•
|
fluctuations in the sales results or other royalty per unit activities of our licensees that impact the calculation of fees due;
|
|
•
|
the timing of the receipt of periodic payments and/or reports from licensees; and
|
|
•
|
fluctuations in the net number of active licensees from period to period.
|
|
|
|
Three Months Ended March 31,
|
||||||
|
|
|
2012
|
|
2011
|
||||
|
|
|
|
|
|
||||
|
Cost of revenues:
|
|
|
|
|
||||
|
Inventor royalties
|
|
$
|
7,594
|
|
|
$
|
13,089
|
|
|
Contingent legal fees
|
|
3,748
|
|
|
9,367
|
|
||
|
|
|
Three Months Ended March 31,
|
|||
|
|
|
2012 vs. 2011
|
|||
|
|
|
|
|
|
|
|
Increase in revenues
|
|
62
|
%
|
|
|
|
Decrease in inventor royalties
|
|
(42
|
)%
|
|
(a)
|
|
Decrease in contingent legal fees expense
|
|
(60
|
)%
|
|
(b)
|
|
Decrease in inventor royalties expense and contingent legal fees expense
|
|
(49
|
)%
|
|
(a), (b)
|
|
|
Three Months Ended March 31,
|
|
||||
|
As a Percentage of Revenue:
|
2012
|
|
2011
|
|
||
|
|
|
|
|
|
||
|
Inventor royalties
|
8
|
%
|
|
21
|
%
|
(a)
|
|
Contingent legal fees expense
|
4
|
%
|
|
15
|
%
|
(b)
|
|
Inventor royalties and contingent legal fees
|
11
|
%
|
|
37
|
%
|
(a),(b)
|
|
(a)
|
The percentage decrease in inventor royalties, as compared to the percentage increase in revenues for the periods presented, was primarily due to a higher percentage of revenues recognized during the three months ended March 31, 2012 having no corresponding inventor royalty obligations, as compared to the revenues recognized during the three months ended March 31, 2011.
|
|
(b)
|
The percentage decrease in contingent legal fees expense, as compared to the percentage increase in revenues for the periods presented, was primarily due to a higher percentage of revenues recognized during the three months ended March 31, 2012 being generated without litigation and therefore having no corresponding contingent legal fee arrangement obligations, as compared to the revenues recognized during the three months ended March 31, 2011.
|
|
|
|
Three Months Ended March 31,
|
||||||
|
|
|
2012
|
|
2011
|
||||
|
|
|
|
|
|
||||
|
Litigation and licensing expenses - patents
|
|
$
|
3,381
|
|
|
$
|
3,534
|
|
|
Amortization of patents
|
|
5,126
|
|
|
3,772
|
|
||
|
|
Three Months Ended March 31,
|
||||||
|
|
2012
|
|
2011
|
||||
|
|
|
|
|
||||
|
Marketing, general and administrative expenses (including non-cash stock compensation expense of $5,090 for the three months ended March 31, 2012, and $2,901 for the three months ended March 31, 2011)
|
$
|
13,731
|
|
|
$
|
9,985
|
|
|
|
Three Months
|
||
|
|
Ended March 31,
|
||
|
|
2012 vs. 2011
|
||
|
|
|
||
|
Addition of business development, engineering and other personnel costs
|
$
|
744
|
|
|
Increase in annual variable performance-based compensation and other variable performance-based compensation costs
|
272
|
|
|
|
Corporate, general and administrative costs
|
541
|
|
|
|
Non-cash stock compensation expense
|
2,189
|
|
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2012
|
|
2011
|
||||
|
|
|
|
|
||||
|
Provision for income taxes
|
$
|
14,747
|
|
|
$
|
7,148
|
|
|
Effective tax rate
|
23
|
%
|
|
35
|
%
|
||
|
•
|
An increase in foreign withholding taxes, totaling $4,439,000, withheld by the applicable foreign tax authority on revenue agreements executed with third party licensees domiciled in certain foreign jurisdictions. The tax provision for the three months ended
March 31, 2012
provides for the utilization of the $11.9 million in foreign taxes withheld during the three months ended
March 31, 2012
, as a credit against income tax expense calculated for financial statement purposes. Tax expense for the three months ended
March 31, 2011
primarily relates to foreign taxes withheld, as described above.
|
|
•
|
For financial reporting purposes, tax expense is calculated without the excess tax benefit related to the exercise and vesting of equity-based incentive awards. Under U.S. generally accepted accounting principles, if a deduction reported on a tax return for an equity-based incentive award exceeds the cumulative compensation cost for those instruments recognized for
|
|
•
|
As of December 31, 2011, we maintained a full valuation allowance against our net deferred tax assets. The net deferred tax liability resulting from the acquisition of ADAPTIX created an additional source of income to utilize against the majority of our existing consolidated net deferred tax assets. In addition, we estimated that certain other deferred tax assets related to foreign tax credits and other state related deferreds, totaling approximately $1.9 million, were more likely than not realizable in future periods. Accordingly, the valuation allowance on the majority of our net deferred tax assets was released, resulting in a first quarter 2012 financial statement income tax benefit of approximately $10.2 million. The offsetting amounts reduced net deferred tax liabilities, $8.3 million of which decreased the net deferred tax liability established in connection with the application of the acquisition method of accounting for the ADAPTIX acquisition.
|
|
•
|
As of March 31, 2012, taxes paid or payable totaled approximately $12.1 million, primarily comprised of foreign withholding taxes, which we anticipate utilizing as a credit against future tax expense as described above, and other state related taxes payable.
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2012
|
|
2011
|
||||
|
|
|
|
|
||||
|
Net cash provided by (used in):
|
|
|
|
||||
|
Operating activities
|
$
|
48,952
|
|
|
$
|
36,452
|
|
|
Investing activities
|
(276,886
|
)
|
|
(704
|
)
|
||
|
Financing activities
|
228,699
|
|
|
175,348
|
|
||
|
|
Payments Due by Period (In thousands)
|
||||||||||||||||||
|
Contractual Obligations
|
Total
|
|
Less than 1 year
|
|
1-3 years
|
|
3-5 years
|
|
More than 5 years
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Operating leases
|
$
|
3,030
|
|
|
$
|
495
|
|
|
$
|
1,451
|
|
|
$
|
1,084
|
|
|
|
|
|
|
Scheduled patent acquisition related payments
|
500
|
|
|
—
|
|
|
250
|
|
|
250
|
|
|
—
|
|
|||||
|
Payments to consultants
|
50
|
|
|
50
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
|
Total contractual obligations
|
$
|
3,580
|
|
|
$
|
545
|
|
|
$
|
1,701
|
|
|
$
|
1,334
|
|
|
$
|
—
|
|
|
EXHIBIT
NUMBER
|
EXHIBIT
|
|
|
|
|
10.1
|
Purchase Agreement, dated as of February 15, 2012, by and between Acacia Research Corporation and
each purchaser party thereto. (1)
|
|
31.1
|
Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934
|
|
31.2
|
Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934
|
|
32.1
|
Certification of Chief Executive Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
|
|
32.2
|
Certification of Chief Financial Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
|
|
101
|
Interactive Data Files Pursuant to Rule 405 of Regulation S-T.*
|
|
(1)
|
Incorporated by reference to Exhibit 10.1 to Acacia Research Corporation’s Current Report on Form 8-K filed on February 16, 2012 (File No. 000-26068).
|
|
|
ACACIA RESEARCH CORPORATION
|
|
|
|
|
|
/
s/ Paul R. Ryan
|
|
|
By: Paul R. Ryan
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer and Duly Authorized Signatory)
|
|
|
|
|
|
/s/ Clayton J. Haynes
|
|
|
By: Clayton J. Haynes
|
|
|
Chief Financial Officer and Treasurer
|
|
|
(Principal Financial and Accounting Officer)
|
|
EXHIBIT
NUMBER
|
EXHIBIT
|
|
|
|
|
10.1
|
Purchase Agreement, dated as of February 15, 2012, by and between Acacia Research Corporation and
each purchaser party thereto. (1)
|
|
31.1
|
Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934
|
|
31.2
|
Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934
|
|
32.1
|
Certification of Chief Executive Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
|
|
32.2
|
Certification of Chief Financial Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
|
|
101
|
Interactive Data Files Pursuant to Rule 405 of Regulation S-T.*
|
|
(1)
|
Incorporated by reference to Exhibit 10.1 to Acacia Research Corporation’s Current Report on Form 8-K filed on February 16, 2012 (File No. 000-26068).
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|